ResApp Diagnostics

ResApp Diagnostics was an Australian digital health and medical device company that developed smartphone-based software for the diagnosis and management of respiratory disease using cough and breathing sound analysis. Its products included ResAppDx for acute respiratory disease diagnosis, SleepCheckRx for prescription screening of moderate to severe sleep apnoea, and SleepCheck for consumer self-assessment of sleep apnoea risk. The company focused on clinically validated, regulatory-approved software that could operate without additional hardware and be integrated into telehealth workflows. ResApp commercialized its technology through mobile applications, telehealth integrations, and licensing collaborations. The business was acquired by Pfizer in 2022 and is no longer an independent public company.